Table A.9.
Univariate and multivariate analyses of factors associated with non-completion of study follow-up (n = 650) compared to those who completed study follow-up (n = 4578) among the first participants enrolled in a cluster in the North American region: Cox proportional hazard model (n = 5228)
| Non-completion of follow-up % | Univariate HR (95%CI) | Multivariate aHR (95%CI) | |
|---|---|---|---|
| Regimen* | |||
| 3HP-DOT (n = 2590) | 11.4 | Reference | Reference |
| 9H-SAT (n = 2638) | 13.5 | 1.2 (1.02–1.39) | |
| Age, years (median = 37) | |||
| <37 (n = 2447) | 14.8 | 1.5 (1.24–1.69) | 1.6 (1.33–1.85) |
| ⩾37 (n = 2781) | 10.4 | Reference | Reference |
| Sex | |||
| Female (n = 2407) | 11.1 | Reference | |
| Male (n = 2821) | 13.6 | 1.3 (1.08–1.48) | |
| Race | |||
| White (n = 2826) | 13.7 | Reference | Reference |
| Black (n = 1487) | 12.7 | 0.9 (0.79–1.12) | 1.0 (0.80–1.21) |
| Asian (n = 722) | 7.5 | 0.5 (0.40–0.71) | 0.5 (0.37–0.70) |
| Other (n = 193)† | 10.4 | 0.8 (0.48–1.18) | 0.8 (0.48–1.27) |
| Ethnicity | |||
| Non-Hispanic (n = 3247) | 10.9 | Reference | |
| Hispanic (n = 1981) | 15.0 | 1.4 (1.20–1.63) | |
| HIV status | |||
| Negative (n = 2729) | 12.8 | Reference | |
| Positive (n = 146) | 12.3 | 1.0 (0.61–1.58) | |
| Unknown (n = 2353) | 12.0 | 0.9 (0.81–1.11) | |
| Country of origin | |||
| Non-US (n = 2966) | 13.3 | Reference | Reference |
| US (n = 2262) | 11.3 | 0.8 (0.72–0.99) | 0.6 (0.50–0.77) |
| Educational level | |||
| ⩽8th grade (n = 799) | 16.4 | 1.9 (1.46–2.46) | 1.5 (1.11–1.96) |
| 9th grade, some college (n = 3320) | 12.6 | 1.4 (1.15–1.78) | 1.1 (0.91–1.44) |
| College or higher (n = 1109) | 9.0 | Reference | Reference |
| Incarceration‡ | |||
| No (n = 4890) | 12.0 | Reference | Reference |
| Yes (n = 338) | 18.9 | 1.7 (1.29–2.16) | 1.5 (1.09–2.0) |
| Unemployed | |||
| No (n = 4568) | 12.2 | Reference | |
| Yes (n = 660) | 13.8 | 1.1 (0.92–1.43) | |
| Homeless§ | |||
| No (n = 4813) | 11.9 | Reference | Reference |
| Yes (n = 415) | 19.0 | 1.7 (1.33–2.14) | 1.8 (1.37–2.48) |
| Alcohol consumption¶ | |||
| No (n = 2302) | 11.8 | Reference | |
| Use (n = 2539) | 12.5 | 1.1 (0.91–1.26) | |
| Abuse (n = 387) | 16.3 | 1.5 (1.11–1.93) | |
| Injection drug use | |||
| No (n = 4984) | 12.3 | Reference | |
| Yes (n = 244) | 14.8 | 1.2 (0.87–1.71) | |
| Chronic liver disease (cirrhosis) | |||
| No (n = 5008) | 12.5 | Reference | |
| Yes (n = 220) | 11.8 | 1.0 (0.65–1.42) | |
| Current smoker | |||
| No (n = 3611) | 11.1 | Reference | Reference |
| Yes (n = 1617) | 15.3 | 1.4 (1.23–1.68) | 1.5 (1.27–1.80) |
| Methadone treatment | |||
| No (n = 5095) | 12.4 | Reference | |
| Yes (n = 133) | 12.0 | 1.0 (0.59–1.59) | |
| Potential for pregnancy | |||
| Not possible (n = 3225) | 12.9 | Reference | |
| Female (n = 1923) | 11.8 | 0.9 (0.76–1.05) | |
| Pregnancy (n = 80) | 7.5 | 0.6 (0.25–1.24) | |
| Enrolling site# | |||
| Missing clinic visit** | |||
| No (n = 4880) | 12.0 | Reference | Reference |
| Yes (n = 349) | 19.5 | 1.7 (1.32–2.19) | 1.5 (1.14–1.91) |
3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).
Includes North American Indian and other participants in the United States and Canada.
History of living in a correctional institution for ⩾1 month prior to enrollment.
History of homelessness or living in a shelter or single room occupancy for ⩾6 months prior to enrollment.
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. Abuse: score of ⩾2 on the CAGE (Cut down, Annoyed, Guilty, Eye-opener) questionnaire.
Enrolling site was anaylsed after a random selection of the refereence value; overall P < 0.001.
Missing at least one of the first three DOT visits for the 3HP-DOT regimen and at least one of the three monthly clinic visits for the 9H-SATregimen, followed by a DOT or monthly visit after the missing DOT/visit, respectively (includes those who did not receive any study dose). No statistically significant interactions resulted between missing an early clinic visit and factors with P ⩽ 0.2 in univariate analysis.
Note: Body mass index was explored, but due to a lack of statistical significance and lack of a meaningful association with the outcome, it was not included in the table/analyses.
HR = hazard ratio; CI = confidence interval; aHR = adjusted HR; H, INH = isoniazid; P, RPT = rifapentine; DOT = directly observed therapy; SAT = self-administered treatment; HIV = human immunodeficiency virus.